COMPANY PROFILE

Starget Pharma

Explore full profile

This company is developing new targeted radiopharmaceutical technologies to treat solid tumors

Ramat Hasharon, IsraelFounded 2019Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Starget Pharma

Starget Pharma specializes in the development of targeted molecular radiotherapy for advanced metastatic cancers. This innovative approach combines radioactive imaging tracers with targeted radiotherapy to diagnose and treat cancer with high precision. The company focuses on creating radioligands, which are composed of a radionuclide for imaging or treatment and a molecular ligand for targeted delivery. These radioligands enable the precise delivery of radiation to cancer cells while minimizing damage to healthy tissues. Starget Pharma's core technology leverages peptide backbone dynamics to enhance the drugability of these radioligands, making them highly effective in treating cancers such as prostate and neuroendocrine tumors. The company operates in the nuclear oncology market, serving healthcare providers and patients with limited or non-existent treatment options. Starget Pharma generates revenue through the development and commercialization of its proprietary radiopharmaceutical products.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Ramat Hasharon, Israel
Employees: 21
Open positions: None listed
Dealroom signal: 76.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Feb 2026	$18M	$72M	STAR TREE VENTURES · Cancer Focus Fund · astr partners · Ilex Medical	↗
EARLY VC✓Equity / VC	Oct 2024	$5.1M	$50M	Cancer Focus Fund	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Starget Pharma website traffic

Latest recorded traffic for Starget Pharma is 1.2K monthly website visits, up 2900% over the last three months. Starget Pharma's team grew 16.7% over the past year.

Latest monthly visits1.2K 3-month web change+2900% 1-year team growth+16.7%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational	2	$165K	$1.6M
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
SPStrike PharmaDevelops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology	Uppsala kommun, Sweden	Operational
OBOne BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases	Paris, France	Operational
NANanoligentThe research and development to clinical phases of innovative cancer treatments based on protein nanoparticles	Cerdanyola del Vallès, Spain	Operational
ODOdimmaFrench biotech company with a unique approach in active personalized cancer immunotherapy	Illkirch, France	Operational
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational